Ames negative; negative for clastogenicity in human fibroblasts; increased micronuclei in human lymphocytes in vitro
“Trilaciclib was negative for mutagenic potential in the Ames assays and negative for clastogenic potential in primary human fibroblasts. Trilaciclib increased micronucleus formation in human peripheral blood lymphocytes in vitro, suggesting clastogenic activity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 65Source ↗
Carcinogenicity
Not conducted
“Carcinogenic potential of trilaciclib has not been assessed in animals.”
✓ VerifiedFDA pharmacology/toxicology review, p. 70Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Not conducted (no fertility, developmental or reproductive toxicity studies)
“No fertility, developmental, or reproductive toxicity studies were conducted in animals.”
✓ VerifiedFDA pharmacology/toxicology review, p. 71Source ↗
Safety pharmacology
Low-potency hERG inhibition (IC50 ≈20 μM) and increased heart rate in dogs; no QT prolongation in animal studies
“There were signals for potential cardiovascular effects of trilaciclib based on a low potency in vitro signal for hERG inhibition (IC50 ≈ 20 μM) and increased heart rate in dogs. In vitro hERG inhibition is a biological marker of QT prolongation but no QT prolongation was observed in animal studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Genotox: Ames
Negative
“Trilaciclib was negative for mutagenic potential in the Ames assays and negative for clastogenic potential in primary human fibroblasts.”
✓ VerifiedFDA pharmacology/toxicology review, p. 65Source ↗
Genotox: in vitro mammalian
Micronucleus in human peripheral blood lymphocytes: positive (confounded by cell-cycle arrest); H2AX in human fibroblasts: negative
“Trilaciclib increased micronucleus formation in human peripheral blood lymphocytes in vitro, suggesting clastogenic activity. However, lymphocytes were shown to be very sensitive to the intended pharmacologic effect of G1 cell cycle by trilaciclib, so the increase in micronuclei seen in HPBL cells was confounded by direct drug-related effects on lymphocyte proliferation.”
✓ VerifiedFDA pharmacology/toxicology review, p. 65Source ↗
Genotox: in vivo
Not conducted
“Genetic toxicity was not assessed in any in vivo assay (e.g., rat liver micronucleus formation in vivo to assess clastogenic potential).”
✓ VerifiedFDA pharmacology/toxicology review, p. 65Source ↗
Carcinogenicity model
Not conducted: patients with SCLC already receiving chemotherapy
“Importantly, trilaciclib clinical dosing is in patients who are receiving chemotherapy to target existing small cell lung cancer so there was little to be gained”
✓ VerifiedFDA pharmacology/toxicology review, p. 70Source ↗
Carcinogenicity timing
Not required (patients with SCLC receiving chemotherapy)
“Importantly, trilaciclib clinical dosing is in patients who are receiving chemotherapy to target existing small cell lung cancer so there was little to be gained”
✓ VerifiedFDA pharmacology/toxicology review, p. 70Source ↗
hERG / QT
hERG IC50 ~20 µM (low potency); no QT prolongation in dog studies
“There were signals for potential cardiovascular effects of trilaciclib based on a low potency in vitro signal for hERG inhibition (IC50 ≈ 20 μM) and increased heart rate in dogs. In vitro hERG inhibition is a biological marker of QT prolongation but no QT prolongation was observed in animal studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative